Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, having at least: human glucagon and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, in one embodiment, the compositions according to the invention further includes a gastrointestinal hormone.
Abstract: In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid), X represents a cationic entity chosen in the group comprising alkali cations, Rb and Rb?, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R?b is a hydrophobic radical -Hy, Q and Hy are as defined above. n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5?n+m?250.
Type:
Application
Filed:
December 7, 2018
Publication date:
September 12, 2019
Applicant:
ADOCIA
Inventors:
You-Ping CHAN, Alexandre GEISSLER, Romain NOEL, Walter ROGER, Richard CHARVET, Nicolas LAURENT
Abstract: A composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analog; and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, wherein the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. The composition may further include a prandial insulin.
Type:
Application
Filed:
December 7, 2018
Publication date:
September 12, 2019
Applicant:
ADOCIA
Inventors:
You-Ping Chan, Alexandre Geissler, Romain Noel, Walter Roger, Richard Charvet, Nicolas Laurent
Abstract: A composition in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, including at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy being according to formula I below: *?GpR?r?GpA?a?GpC)p ??Formula I wherein the composition does not comprise a basal insulin the isoelectric point pI of which is comprised from 5.8 to 8.5. It also relates to a composition wherein it further includes prandial insulin.
Abstract: A composition is in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, and includes at least: insulin glargine, a co-polyamino acid bearing carboxylate charges and hydrophobic Hy radicals, the co-polyamino acid being made of glutamic or aspartic units and the hydrophobic Hy radicals from following formula I below: *?GpR?r?GpA?a?GpC)p?? Formula I The composition does not include a basal insulin whose isoelectric point pI is from 5.8 to 8.5. A composition further includes prandial insulin.
Abstract: The invention also relates to physically stable compositions in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, comprising at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and Hy hydrophobic radicals, In one embodiment, the compositions according to the invention also comprise a gastro-intestinal hormone.
Type:
Application
Filed:
December 7, 2018
Publication date:
September 12, 2019
Applicant:
ADOCIA
Inventors:
You-Ping CHAN, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
Abstract: Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.
Type:
Application
Filed:
December 7, 2018
Publication date:
September 12, 2019
Applicant:
ADOCIA
Inventors:
You-Ping CHAN, Alexandre GEISSLER, Romain NOEL, Walter ROGER, Richard CHARVET, Nicolas LAURENT
Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, including at least: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
Type:
Grant
Filed:
June 7, 2017
Date of Patent:
August 20, 2019
Assignee:
ADOCIA
Inventors:
Alexandre Geissler, Ségolène Laage, Richard Charvet, Olivier Soula
Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, includes at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions include, in addition, a gastrointestinal hormone.
Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.
Abstract: A composition in the form of an injectable aqueous solution, with pH from 3.5 to 4.4, including at least human insulin A21G and at least one glucagon suppressor with prandial action. In an embodiment, the glucagon suppressor with prandial action is selected from an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). In an embodiment, the glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. In an embodiment, the glucagon suppressor peptide with prandial action is pramlintide. Also, a method for obtaining human insulin A21G, includes at least one step of reacting human insulin A21G, B31R, B32R (insulin glargine) with rat carboxypeptidase B at an insulin/carboxypeptidase ratio from 500 to 2000, at a pH from 7.5 to 8.5 and a temperature from 20 to 30° C.
Abstract: In embodiments, the present disclosure provides an aqueous pharmaceutical composition that includes insulin in hexameric form, and citric acid or a salt thereof at a concentration from 6 to 30 mM, wherein the composition is suitable for injecting into a diabetic patient to treat diabetes.
Abstract: A composition in the form of an injectable aqueous solution, the pH of which is from 6.6 to 7.8, comprises at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) an anionic compound bearing carboxylate charges and hydrophobic radicals. The composition may also include a prandial insulin.
Type:
Application
Filed:
April 11, 2018
Publication date:
August 23, 2018
Applicant:
ADOCIA
Inventors:
Olivier SOULA, Richard CHARVET, Alexandre GEISSLER
Abstract: An injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: ?GpR?r?GpA?a?GpC)p ??I wherein the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition wherein it moreover comprises a prandial insulin.
Abstract: The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.6 and 7.8, including at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) a hydrophobized anionic polymer. In one embodiment, the compositions according to the invention also include a prandial insulin.
Abstract: A storage-stable pharmaceutical composition includes an aqueous solution of at least an antibody-derived therapeutically active protein chosen amongst antibody, nanobody or fusion protein and an amount effective to stabilize the antibody-derived therapeutically active protein of at least one lauryldimethylamineoxide and/or of one of its amine oxide analogs.
Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.
Type:
Application
Filed:
May 31, 2017
Publication date:
December 28, 2017
Applicant:
ADOCIA
Inventors:
Olivier SOULA, Gerard SOULA, Emmanuel DAUTY, Richard CHARVET
Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, including at least: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.